What is HC Wainwright’s Estimate for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Day One Biopharmaceuticals in a research note issued on Thursday, April 3rd. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.37) per share for the quarter, down from their prior estimate of ($0.28). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.75 EPS, FY2028 earnings at $0.84 EPS and FY2029 earnings at $1.35 EPS.

Several other equities research analysts also recently issued reports on DAWN. The Goldman Sachs Group cut their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Wedbush restated an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Bank of America lowered their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.29.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $7.02 on Monday. The firm has a market cap of $711.51 million, a P/E ratio of -6.82 and a beta of -1.24. Day One Biopharmaceuticals has a 52 week low of $6.65 and a 52 week high of $18.07. The firm’s 50-day simple moving average is $10.01 and its 200 day simple moving average is $12.33.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $866,000. Charles Schwab Investment Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after purchasing an additional 64,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after buying an additional 57,601 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after buying an additional 136,458 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Day One Biopharmaceuticals by 142.1% during the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock worth $10,052,000 after buying an additional 423,543 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Activity

In related news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company’s stock, valued at $473,639.92. This represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.